Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
© The Author(s). 2017
Received: 17 May 2017
Accepted: 19 May 2017
Published: 1 June 2017
After publication of the Review article  it was brought to our attention that the sentence at the bottom of the section entitled Tiotropium bromide (pag 5) must be corrected as follows: “Following positive large efficacy and safety trials in asthma, in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat® at a dose of 5 μg once (delivered in two inhalation of 2.5 μg each) to patients with asthma, which was also approved in more than 50 countries, including Japan. In September 2015 the Food and Drug Administration confirmed the same indication, but with a dosage of 2.5 μg once daily (delivered in two inhalation of 1.25 μg each); the latter being extended for patients aged 6 and older since 16th February 2017.”
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.